72559-06-9

• 常用中文名：利福布汀
• 常用英文名：Rifabutin
• CAS号：72559-06-9
• 分子式：C₄₆H₆₂N₄O₁₁
• 分子量：847.005
• 相关类别： 原料药 抗生素类药物 利福霉素类药
• 发布时间：2018-05-15 08:00:00
• 更新时间：2026-06-30 14:01:19
• Rifabutin (Ansamycin) 是半合成的安莎霉素抗生素,具有抗分枝杆菌特性。

名称

• 中文名: 利福布丁
• 英文名: Rifabutin
• 中文别名: 利福布丁/利福布汀; 利福布汀 标准品; 利福布汀13; 氘7-利福布丁; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-乙酰氧基-6,18,20-三羟基-14-甲氧基-7,9,15,17,19,21,25-七甲基-1′-(2-甲基丙基)螺[9,4-(环氧十; 4-脱氧-3,4-[2-螺(N-异丁基-4-哌啶基)]-(1H)-咪唑并-(2,5-双氢)利福霉素S; 利福布丁 标准品; 4-N-异丁基螺哌啶酮利福霉素S; 利福布丁(标准品); (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-乙酰氧基-6,18,20-三羟基-14-甲氧基-7,9,15,17,19,21,25-七甲基-1′-(2-甲基丙基)螺[9,4-(环氧十五碳烷[1,11,13] TRIENIMINO)-2H-呋喃并[2′,3′:7,8]萘并[1,2-D]咪唑-2,4'-哌啶]-5,10,26(3H,9H)-三酮; 4-N-异丁基螺哌啶利福霉素 S; 利福布丁,10 MM DMSO 溶液; 螺哌啶利福霉素S; 丙酚替诺福韦(替诺福韦艾拉酚胺)检测标准品; 福布汀; 利福布丁(对照品); RIFABUTIN利福布汀; 利福布汀-D7; 利福布汀 利福布丁; 利福布汀/A1A; 利福布汀(安莎霉素)
• 英文别名: Levofloxacin D7; Collagen proline hydroxylase inhycobutin; Rifabutin (Mycobutin); 4-Deoxw3，4-[2-spiro(N-isobutyl-4-pipendyl)]-(1H)-imidazo-(2，5-dihydro)rifamycin S; Ansatipine (Fmitalia); Ansamycin (Rifabutin); 4-deoxo-3,4-[2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo]-rifamicin S; 1,4-dihydro-1-deoxy-1’,4-didehydro-5’-(2-methylpropyl)-1-oxorifamycinxiv; 1’,4-Didehydro-1-deoxy-1,4-dihydro-5’-(2-methylpropyl)-1-oxo; Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo; Rifamycin XIV, Ansamycin; RIFABUTIN; Rifabutin (Ansamycin); D7-Rifabutin; MYCOBUTIN; ANSAMYCIN; LM 427; ANSATIPINE; Rifabutin, 10 mM in DMSO; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-htamethylspiro(9,4-oxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperidine)-5,10,26(3H,9H)-trione,16-acetate; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(Acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-htamethyl-1′-(2-methylpropyl)spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo[2′,3′:7,8]naphth[1,2-d]imidazole-2,4′-piperidine]-5,10,26; 1',4-Didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-N-ISOBUTYLSPIROPIPERIDYIFAMYCIN S; Mycobutin; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; Lifu pudding; RIFABUTINE(LM－427、ANSAMYCIN、ANSATIPIN、ANSMYCIN、MYCOBUTIN):4-N-ISOBUTYLSPIROPIPERIDYIFAMYCIN S; RifabutinQ: What is Rifabutin Q: What is the CAS Number of Rifabutin Q: What is the storage condition of Rifabutin Q: What e the applications of Rifabutin; Rifabutin Impurity; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-htamethyl-1'-(2-methylpropyl)-spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione; Spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione,16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-htamethyl-1'-(2-methylpropyl)-,[9S-(9R*,12E,14R*,15S*,16R*,17S; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-hta-methyl-spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo-[2',3':7,8]-naphth[1,2-d]imidazol-2,4'-piperidin]-5,10,26-(3H,9H)-trione; Rifabutin-d7; Rifabutin Impurity 13; Spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-htamethyl-1'-(2-methylpropyl)-, (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z); Levobutin; Rifabutin //BP; Rifabutin (50 mg); 1,4-dihydro-1-deoxy-1’,4-didehydro-5’-(2-methylpropyl)-1-oxo-rifamycinxi; Ansatipine; 4-deoxo-3,4-(2-spiro(n-isobutyl-4-piperidyl)-2,5-dihydro-1h-imidazo)-rifamyc; 1',4-didehydro-1-desoxi-1,4-di-hydro-5'-(2-methyl-propyl)-1-oxo-rifamycin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-htamethyl-1'-(2-methylpropyl)-spiro[9,4-oxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidaz; 6,9-dihydro-5,17,19,21-tetrahydroxy-8,9-[2-spiro-(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo]-23-methoxy-2,4,12,16,18,20,22-heptamethyl-6-oxo-2,7-epoxypentadeca-[1,11,13]-trienimine-2H-furo[2',3',7,8]nafto[1,2-d]imidazolo-2,4'-piperidine-5,10,26. (3H,9H)-trione-16-acetate; Ansamycin; Rifabatin; Rifabutin (LM427); Mycobutin (Fmitalia); RIFABUTINE; Rifabutin CRS; lm427; antibioticlm427

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 969.6±65.0 °C at 760 mmHg
• 熔点: 169-171ºC
• 分子式: C₄₆H₆₂N₄O₁₁
• 分子量: 847.005
• 闪点: 540.2±34.3 °C
• 精确质量: 846.441528
• PSA: 205.55000
• LogP: 3.45
• 外观性状: 红色-紫罗兰色结晶粉末
• 蒸汽压: 0.0±0.3 mmHg at 25°C
• 折射率: 1.623
• 储存条件: Amber Vial, -20°C Freezer, Under Inert Atmosphere
• 水溶解性: DMSO: >5mg/mL

生物活性

• 描述: Rifabutin (Ansamycin) 是半合成的安莎霉素抗生素,具有抗分枝杆菌特性。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染
• 靶点:

  Antibacterial

• 体外研究: 利福布丁主要是用于治疗结核病的杀菌抗生素药物。它对细菌的作用是基于DNA依赖性RNA聚合酶阻断药物利福霉素S.,一种半合成衍生物。例如,它在高抗性分枝杆菌,革兰氏阳性菌(和一些对革兰氏阴性菌有效)中有效,但也对结核分枝杆菌,麻风杆菌和胞内分枝杆菌有效。利福布丁是一种抗生素;抗肿瘤。利福布汀干扰HSP-90分子伴侣,增强泛素化和蛋白质降解,并使细菌RNA聚合酶失活。
• 参考文献:

  [1]. Review Article: Rifabutin in the Treatment of Refractory Helicobacter pylori Infection J. P. Gisbert, X. Calvet Issue Alimentary Pharmacology & Therapeutics Volume 35, Issue 2, pages 209-221, January 2012

  [2]. Vourvahis M, Davis J, Wang R, Layton G, Choo HW, Chong CL, Tawadrous M.Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-o-desacetyl-rifabutin in healthy subjects.Antimicrob Agents Chemother. 2012 Aug;56(8):4303-9.

  [3]. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X.Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.Aliment Pharmacol Ther. 2012 Apr;35(8):941-7. doi: 10.1111/j.1365-2036.2012.05053.x.

  [4]. Gisbert JP, Calvet X.Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.Aliment Pharmacol Ther. 2012 Jan;35(2):209-21. doi: 10.1111/j.1365-2036.2011.04937.x.

  [5]. Horne DJ, Spitters C, Narita M.Experience with rifabutin replacing rifampin in the treatment of tuberculosis.Int J Tuberc Lung Dis. 2011 Nov;15(11):1485-9, i.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : VJ6700000 CHEMICAL NAME : Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl )-1-oxo- CAS REGISTRY NUMBER : 72559-06-9 LAST UPDATED : 199709 DATA ITEMS CITED : 11 MOLECULAR FORMULA : C46-H62-N4-O11 MOLECULAR WEIGHT : 847.12 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - man DOSE/DURATION : 60 mg/kg/14D-I TOXIC EFFECTS : Blood - agranulocytosis REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 348,685,1996 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - woman DOSE/DURATION : 84 mg/kg/14D-I TOXIC EFFECTS : Blood - agranulocytosis REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 348,685,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 51 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3322 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 266 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Primate - monkey DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 9100 mg/kg/13W-C TOXIC EFFECTS : Liver - other changes Kidney, Ureter, Bladder - other changes Blood - changes in spleen REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 29120 mg/kg/1Y-I TOXIC EFFECTS : Blood - normocytic anemia Endocrine - changes in spleen weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 47 mg/kg/1Y-C TOXIC EFFECTS : Blood - normocytic anemia Blood - changes in spleen Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) REFERENCE : ETPAEK Experimental and Toxicologic Pathology. (Gustav Fischer Verlag Jena, Postfach 100537, D-07705 Jena, Germany) V.44- 1992- Volume(issue)/page/year: 47,1,1995

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危险品运输编码: NONH for all modes of transport
• RTECS号: VJ6700000
• 海关编码: 2941903000

制备

【方法1】
以1，4-二氢利福霉素S为原料，经溴化，亚硝基取代，氢化，氨化，再和N-异丁基哌啶酮反应，即可得到利福布汀。

海关

海关编码	2941903000